Secondary Logo

Journal Logo

September 2019 - Volume 74 - Issue 3

  • George W. Booz, PhD, FAHA
  • 0160-2446
  • 1533-4023
  • 12 issues per year
  • Cardiac & Cardiovascular Systems 69/136, Pharmacology & Pharmacy 151/267
  • 2.371

The September issue introduces the first half of guest editor Antonio Abbate's series that brings together international experts to discuss the role of the NLRP3 inflammasome in cardiac pathophysiology. Besides presenting a detailed description of the molecular aspects of this critical component of innate immunity, the series tackles its role in injury sensing and amplification of the inflammatory response; cell-specific inflammasome signaling; evidence supporting the potential of inhibiting the inflammasome and caspase-1 in limiting myocardial ischemia-reperfusion injury; its activation by chronic metabolic stress in diet-induced obesity and diabetes, thereby linking impairments in metabolism to chronic inflammation and cardiovascular dysfunction; other functions that may in part be separate from inflammation and are cardioprotective; the biochemistry and molecular aspects of inflammasome inhibitors (from pre-existing drugs to drugs in phase I-II clinical development specifically designed to inhibit NLRP3); and an analysis and summary of strategies to inhibit NLRP3 inflammasome activity and effects on clinical outcomes. Our readers should find this extensive series valuable for understanding this novel therapeutic target.The September issue introduces the first half of guest editor Antonio Abbate's series that brings together international experts to discuss the role of the NLRP3 inflammasome in cardiac pathophysiology. Besides presenting a detailed description of the molecular aspects of this critical component of innate immunity, the series tackles its role in injury sensing and amplification of the inflammatory response; cell-specific inflammasome signaling; evidence supporting the potential of inhibiting the inflammasome and caspase-1 in limiting myocardial ischemia-reperfusion injury; its activation by chronic metabolic stress in diet-induced obesity and diabetes, thereby linking impairments in metabolism to chronic inflammation and cardiovascular dysfunction; other functions that may in part be separate from inflammation and are cardioprotective; the biochemistry and molecular aspects of inflammasome inhibitors (from pre-existing drugs to drugs in phase I-II clinical development specifically designed to inhibit NLRP3); and an analysis and summary of strategies to inhibit NLRP3 inflammasome activity and effects on clinical outcomes. Our readers should find this extensive series valuable for understanding this novel therapeutic target.


Current Issue Highlights





Impact of Postdischarge Bleeding on Long-Term Mortality in Percutaneous Coronary Intervention Patients Taking Oral Anticoagulants

Yoshida, Ruka; Ishii, Hideki; Morishima, Itsuro; More

Journal of Cardiovascular Pharmacology. 74(3):210-217, September 2019.



Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT)

Trankle, Cory R.; Wohlford, George; Buckley, Leo F.; More

Journal of Cardiovascular Pharmacology. 74(3):266-269, September 2019.

`